Weekly Rundown: Small-Cap Stocks with Key Catalysts (July 21-25)

Following a review of regulatory filings and corporate announcements, we’ve compiled the key catalysts likely to shape small-cap activity in the coming week. Below is our outlook for July 21–25.

--

Upcoming catalysts for the week:

Monday, July 21, 2025

● GRO - 4:30 PM ET Catalyst: Conference call to discuss new partnership with Fictor Energia and equity financing for the Autazes Project.

● LZM - 10:00 AM ET Catalyst: Virtual presentation of Feasibility Study highlights.

Tuesday, July 22, 2025

● ONCY - 1:00 PM ET Catalyst: KOL webinar on pelareorep in mPDAC and GI cancers.

● MSGM - Catalyst: Official 1.0 release of Le Mans Ultimate, exiting Early Access phase.

● LUCY - Catalyst: Launch of Reebok x Lucyd showcase at Smartech NYC flagship.

Wednesday, July 23, 2025

● BFRG - 4:15 PM ET Catalyst: Investor webinar hosted by RedChip featuring CEO insights on new AI platforms.

● FFAI - Catalyst: Private reception at Capitol Hill Club to showcase innovation in line with U.S. trade policy.

Thursday, July 24, 2025

● RR - Catalyst: ADAM robot featured at NASA’s “Legacy of Launch” 75th Anniversary event.

● UIS - 2:00 PM ET Catalyst: Conference call on debt restructuring and pension strategy overhaul.

● RSLS - Catalyst: Special shareholder meeting to vote on merger with Vyome and asset sale to Biorad Medisys.

Friday, July 25, 2025

● GFAI - Catalyst: High-profile rebranding event and product launch in Bangkok (Smart Cash & Retail Solutions).

● XWEL - Catalyst: Grand opening of first non-airport wellness center in Clearwater, Florida.

● CTSO - Catalyst: Filing of “Request for Reconsideration” with Health Canada for DrugSorb-ATR approval.

● ORKT - Catalyst: Official public launch of eMOBIQ® AI — an enterprise-grade, AI-first no-code development platform.

Ongoing (July 20–24, 2025)

● CGEN - Catalyst: Presentation at the International Society for Computational Biology (ISMB) in Liverpool, UK — key research on TNBC tumor subtypes and immune evasion mechanisms.

Available On Demand Starting Tuesday, July 22, 2025

JTC Virtual Investor "What's Your Story" Summer Spotlight

Catalyst: On-demand investor presentations featuring company leadership discussing their mission, development milestones, and product pipelines.

Participating Companies:

● Akari Therapeutics, Plc (AKTX)

● Autonomix Medical, Inc. (AMIX)

● CNS Pharmaceuticals, Inc. (CNSP)

● enVVeno Medical Corporation (NVNO)

● GRI Bio, Inc. (GRI)

● Moleculin Biotech, Inc. (MBRX)

● Outlook Therapeutics, Inc. (OTLK)

● Palisade Bio, Inc. (PALI)

● Senti Biosciences, Inc. (SNTI)

End of July 2025 – Expected Catalysts

● ASTI (Ascent Solar Technologies, Inc.) Catalyst: Delivery of thin-film PV units to a Colorado-based power systems provider for evaluation. Significance: Potential integration into commercial product lines and demonstration of fast fulfillment capabilities.

● PRFX (PainReform Ltd.) Catalyst: Expected closing of strategic investment agreement with LayerBio Inc., a biotech company developing non-opiate ophthalmic treatments. Significance: Represents PainReform's expansion into ophthalmology and enhancement of its specialty pharma pipeline. Timeline: Deal expected to close by end of July 2025, pending customary conditions.

● ADIL (Adial Pharmaceuticals, Inc.) Catalyst: FDA End-of-Phase 2 (EOP2) Meeting scheduled for July 29, 2025, to review the development path for AD04, a serotonin-3 receptor antagonist for Alcohol Use Disorder (AUD). Significance: Key regulatory milestone that could enable advancement to late-stage trials.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.